866-997-4948(US-Canada Toll Free)

Glioma Pipeline Review, H2 2012

Published By :

Global Markets Direct

Published Date : Oct 2012

Category :

Oncology

No. of Pages : 325 Pages


Glioma Pipeline Review, H2 2012

Global Markets Directs, 'Glioma Pipeline Review, H2 2012', provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for Glioma, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Glioma. Glioma Pipeline Review, Half Year is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • A snapshot of the global therapeutic scenario for Glioma.
  • A review of the Glioma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • Coverage of products based on various stages of development ranging from discovery till registration stages.
  • A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
  • Coverage of the Glioma pipeline on the basis of route of administration and molecule type.
  • Key discontinued pipeline projects.
  • Latest news and deals relating to the products.

Reasons to buy

  • Identify and understand important and diverse types of therapeutics under development for Glioma.
  • Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
  • Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
  • Devise corrective measures for pipeline projects by understanding Glioma pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
Table of Contents

Table of Contents 2

List of Tables 10
List of Figures 15
Introduction 16
Global Markets Direct Report Coverage 16
Glioma Overview 17
Therapeutics Development 18
An Overview of Pipeline Products for Glioma 18
Glioma Therapeutics under Development by Companies 20
Glioma Therapeutics under Investigation by Universities/Institutes 29
Late Stage Products 39
Comparative Analysis 39
Mid Clinical Stage Products 40
Comparative Analysis 40
Early Clinical Stage Products 41
Comparative Analysis 41
Discovery and Pre-Clinical Stage Products 42
Comparative Analysis 42
Glioma Therapeutics Products under Development by Companies 43
Glioma Therapeutics Products under Investigation by Universities/Institutes 53
Companies Involved in Glioma Therapeutics Development 78
Boehringer Ingelheim GmbH 78
F. Hoffmann-La Roche Ltd. 79
Vical Incorporated 80
Amgen Inc. 81
Sanofi-Aventis 82
AstraZeneca PLC 83
Eli Lilly and Company 84
Viralytics Ltd. 85
GlaxoSmithKline plc 86
Genentech, Inc. 87
Nektar Therapeutics 88
Antigenics, Inc. 89
MedImmune LLC 90
Merck & Co., Inc. 91
Lentigen Corporation 92
Sangamo BioSciences, Inc. 93
Plexxikon Inc. 94
YM BioSciences Inc. 95
Light Sciences Oncology, Inc. 96
Celltrion, Inc. 97
Ark Therapeutics Group plc 98
Histogen, Inc. 99
Novartis AG 100
Actelion Ltd 101
Astellas Pharma Inc. 102
Eisai Co., Ltd. 103
Nippon Shinyaku Co., Ltd. 104
Pfizer Inc. 105
Teva Pharmaceutical Industries Limited 106
Cell Therapeutics, Inc. 107
Exelixis, Inc. 108
Aduro BioTech 109
Alfacell Corporation 110
Merck KGaA 111
GW Pharmaceuticals plc 112
Celldex Therapeutics, Inc. 113
AEterna Zentaris Inc. 114
ImmunoCellular Therapeutics, Ltd. 115
Lixte Biotechnology Holdings, Inc. 116
Northwest Biotherapeutics, Inc. 117
Cleveland BioLabs, Inc. 118
Oncolytics Biotech Inc. 119
Oncothyreon Inc 120
Peregrine Pharmaceuticals, Inc. 121
Telik, Inc. 122
Pharmacyclics, Inc. 123
PhytoMedical Technologies, Inc. 124
Cytomedix, Inc. 125
Transgene SA 126
Prana Biotechnology Limited 127
Threshold Pharmaceuticals, Inc. 128
Natco Pharma Limited 129
Proximagen Neuroscience plc. 130
e-Therapeutics plc 131
Rexahn Pharmaceuticals, Inc. 132
Cancer Research Technology Limited 133
Spectrum Pharmaceuticals, Inc. 134
Antisense Pharma GmbH 135
INSYS Therapeutics, Inc. 136
Ambit Biosciences Corporation 137
Immupharma Plc 138
Adnexus Therapeutics, Inc. 139
immatics biotechnologies GmbH 140
Advantagene, Inc. 141
Apogenix GmbH 142
BioNumerik Pharmaceuticals, Inc. 143
Ascenta Therapeutics, Inc. 144
Oncoscience AG 145
Hawthorn Pharmaceuticals, Inc. 146
Diffusion Pharmaceuticals LLC 147
MacroGenics, Inc. 148
Fina Biotech 149
Arno Therapeutics, Inc. 150
Merrimack Pharmaceuticals, Inc. 151
Nobelpharma Co., Ltd. 152
Deciphera Pharmaceuticals, LLC 153
Vascular Biogenics Ltd. 154
Burzynski Research Institute, Inc. 155
Stemline Therapeutics, Inc. 156
BioCancell Therapeutics, Inc. 157
Axelar AB 158
Advenchen Laboratories, LLC 159
Viral Genetics, Inc. 160
NOXXON Pharma AG 161
ChemoCentryx, Inc. 162
Cellceutix Corporation 163
TVAX Biomedical, LLC 164
Sirnaomics, Inc. 165
to-BBB technologies BV 166
Lipopharma 167
ZGene A/S 168
Kringle Pharma, Inc. 169
Nexgenix Pharmaceuticals, LLC 170
Archer Biosciences, Inc 171
Regulus Therapeutics Inc. 172
Lee's Pharmaceutical Holdings Limited 173
Lipocine Inc. 174
n.v. BRUCELLS s.a. 175
R&D Systems, Inc. 176
Eurofarma 177
TAU Therapeutics, LLC 178
EirGen Pharma Ltd. 179
Tocagen Inc 180
Ampio Pharmaceuticals, Inc. 181
CytomX, LLC. 182
Glioma Therapeutics Assessment 183
Assessment by Monotherapy Products 183
Assessment by Combination Products 184
Assessment by Route of Administration 185
Assessment by Molecule Type 187
Drug Profiles 189
enzastaurin hydrochloride - Drug Profile 189
Product Description 189
Mechanism of Action 189
R&D Progress 189
cediranib maleate - Drug Profile 191
Product Description 191
Mechanism of Action 191
R&D Progress 191
rindopepimut - Drug Profile 193
Product Description 193
Mechanism of Action 193
R&D Progress 193
bevacizumab - Drug Profile 194
Product Description 194
Mechanism of Action 194
R&D Progress 194
bevacizumab - Drug Profile 196
Product Description 196
Mechanism of Action 196
R&D Progress 196
cilengitide - Drug Profile 198
Product Description 198
Mechanism of Action 198
R&D Progress 198
DCVax-L - Drug Profile 200
Product Description 200
Mechanism of Action 200
R&D Progress 200
Antineoplaston A-10 + Antineoplaston AS2-1 - Drug Profile 202
Product Description 202
Mechanism of Action 202
R&D Progress 202
cintredekin besudotox - Drug Profile 204
Product Description 204
Mechanism of Action 204
R&D Progress 204
trabedersen - Drug Profile 206
Product Description 206
Mechanism of Action 206
R&D Progress 206
Recentin + Lomustine - Drug Profile 208
Product Description 208
Mechanism of Action 208
R&D Progress 208
Bevacizumab + Temozolomide - Drug Profile 209
Product Description 209
Mechanism of Action 209
R&D Progress 209
Nimotuzumab + Temozolomide + Radiation Therapy - Drug Profile 238
Product Description 238
Mechanism of Action 238
R&D Progress 238
erlotinib hydrochloride - Drug Profile 239
Product Description 239
Mechanism of Action 239
R&D Progress 239
Radiation Therapy + Procarbazine + ACNU - Drug Profile 241
Product Description 241
Mechanism of Action 241
R&D Progress 241
Radiation Therapy + ACNU - Drug Profile 242
Product Description 242
Mechanism of Action 242
R&D Progress 242
Temozolomide + Etoposide + Trofosfamid - Drug Profile 243
Product Description 243
Mechanism of Action 243
R&D Progress 243
Thioguanine + Procarbazine + Lomustine + Vincristine - Drug Profile 245
Product Description 245
Mechanism of Action 245
R&D Progress 245
Temozolomide + Radiotherapy - Drug Profile 266
Product Description 266
Mechanism of Action 266
R&D Progress 266
Eir-060 - Drug Profile 267
Product Description 267
Mechanism of Action 267
R&D Progress 267
Eir-080 - Drug Profile 268
Product Description 268
Mechanism of Action 268
R&D Progress 268
Glioma Therapeutics Drug Profile Updates 269
Glioma Therapeutics Discontinued Products 279
Glioma Therapeutics - Dormant Products 285
Glioma Product Development Milestones 316
Featured News & Press Releases 316
Oct 02, 2012: Cell Therapeutics' Opaxio Receives US Orphan Drug Designation For Treatment Of Glioblastoma Multiforme 316
Sep 30, 2012: Threshold Pharma Announces Preliminary Data From Phase I/II Study Of TH-302 In Combination With Bevacizumab In Patients With Recurrent Glioblastoma 317
Sep 26, 2012: ImmuPharma Initiates Phase I/II Study Of Cancer Therapeutic IPP-204106 318
Sep 26, 2012: Threshold Pharma Announces Presentations On TH-302 In Pancreatic Cancer And Glioblastoma At ESMO 319
Sep 05, 2012: ImmunoCellular Therapeutics Completes Enrollment Of Phase II Trial Of ICT-107 In Glioblastoma 319
Aug 28, 2012: Immatics Biotechnologies Announces Presentation Of IMA950 data At EANO 2012 320
Aug 23, 2012: Northwest Bio Receives Regulatory Approval To Proceed With Phase III Trial In Uk 320
Aug 10, 2012: Genentech Announces Avastin Combination Therapy Meets Co-Primary Endpoint In Phase III Brain Cancer Study 321
Aug 08, 2012: Northwest Bio Expands Worldwide Production Capacity For DCVax-L 322
Aug 08, 2012: ImmunoCellular Announces Publication Of Phase I Trial Data Of ICT-107 In Prestigious Medical Journal, Cancer Immunology, Immunotherapy 323

Appendix 324
Methodology 324
Coverage 324
Secondary Research 324
Primary Research 324
Expert Panel Validation 324
Contact Us 325
Disclaimer 325

List of Table


Number of Products Under Development for Glioma, H2 2012 18
Products under Development for Glioma Comparative Analysis, H2 2012 19
Number of Products under Development by Companies, H2 2012 21
Number of Products under Development by Companies, H2 2012 (Contd..1) 22
Number of Products under Development by Companies, H2 2012 (Contd..2) 23
Number of Products under Development by Companies, H2 2012 (Contd..3) 24
Number of Products under Development by Companies, H2 2012 (Contd..4) 25
Number of Products under Development by Companies, H2 2012 (Contd..5) 26
Number of Products under Development by Companies, H2 2012 (Contd..6) 27
Number of Products under Development by Companies, H2 2012 (Contd..7) 28
Number of Products under Investigation by Universities/Institutes, H2 2012 30
Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..1) 31
Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..2) 32
Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..3) 33
Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..4) 34
Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..5) 35
Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..6) 36
Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..7) 37
Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..8) 38
Comparative Analysis by Late Stage Development, H2 2012 39
Comparative Analysis by Mid Clinical Stage Development, H2 2012 40
Comparative Analysis by Early Clinical Stage Development, H2 2012 41
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H2 2012 42
Products under Development by Companies, H2 2012 43
Products under Development by Companies, H2 2012 (Contd..1) 44
Products under Development by Companies, H2 2012 (Contd..2) 45
Products under Development by Companies, H2 2012 (Contd..3) 46
Products under Development by Companies, H2 2012 (Contd..4) 47
Products under Development by Companies, H2 2012 (Contd..5) 48
Products under Development by Companies, H2 2012 (Contd..6) 49
Products under Development by Companies, H2 2012 (Contd..7) 50
Products under Development by Companies, H2 2012 (Contd..8) 51
Products under Development by Companies, H2 2012 (Contd..9) 52
Products under Investigation by Universities/Institutes, H2 2012 53
Products under Investigation by Universities/Institutes, H2 2012 (Contd..1) 54
Products under Investigation by Universities/Institutes, H2 2012 (Contd..2) 55
Products under Investigation by Universities/Institutes, H2 2012 (Contd..3) 56
Products under Investigation by Universities/Institutes, H2 2012 (Contd..4) 57
Products under Investigation by Universities/Institutes, H2 2012 (Contd..5) 58
Products under Investigation by Universities/Institutes, H2 2012 (Contd..6) 59
Products under Investigation by Universities/Institutes, H2 2012 (Contd..7) 60
Products under Investigation by Universities/Institutes, H2 2012 (Contd..8) 61
Products under Investigation by Universities/Institutes, H2 2012 (Contd..9) 62
Products under Investigation by Universities/Institutes, H2 2012 (Contd..10) 63
Products under Investigation by Universities/Institutes, H2 2012 (Contd..11) 64
Products under Investigation by Universities/Institutes, H2 2012 (Contd..12) 65
Products under Investigation by Universities/Institutes, H2 2012 (Contd..13) 66
Products under Investigation by Universities/Institutes, H2 2012 (Contd..14) 67
Products under Investigation by Universities/Institutes, H2 2012 (Contd..15) 68
Products under Investigation by Universities/Institutes, H2 2012 (Contd..16) 69
Products under Investigation by Universities/Institutes, H2 2012 (Contd..17) 70
Products under Investigation by Universities/Institutes, H2 2012 (Contd..18) 71
Products under Investigation by Universities/Institutes, H2 2012 (Contd..19) 72
Products under Investigation by Universities/Institutes, H2 2012 (Contd..20) 73
Products under Investigation by Universities/Institutes, H2 2012 (Contd..21) 74
Products under Investigation by Universities/Institutes, H2 2012 (Contd..22) 75
Products under Investigation by Universities/Institutes, H2 2012 (Contd..23) 76
Products under Investigation by Universities/Institutes, H2 2012 (Contd..24) 77
Boehringer Ingelheim GmbH, H2 2012 78
F. Hoffmann-La Roche Ltd., H2 2012 79
Vical Incorporated, H2 2012 80
Amgen Inc., H2 2012 81
Sanofi-Aventis, H2 2012 82
AstraZeneca PLC, H2 2012 83
Eli Lilly and Company, H2 2012 84
Viralytics Ltd., H2 2012 85
GlaxoSmithKline plc, H2 2012 86
Genentech, Inc., H2 2012 87
Nektar Therapeutics, H2 2012 88
Antigenics, Inc., H2 2012 89
MedImmune LLC, H2 2012 90
Merck & Co., Inc., H2 2012 91
Lentigen Corporation, H2 2012 92
Sangamo BioSciences, Inc., H2 2012 93
Plexxikon Inc., H2 2012 94
YM BioSciences Inc., H2 2012 95
Light Sciences Oncology, Inc., H2 2012 96
Celltrion, Inc., H2 2012 97
Ark Therapeutics Group plc, H2 2012 98
Histogen, Inc., H2 2012 99
Novartis AG, H2 2012 100
Actelion Ltd, H2 2012 101
Astellas Pharma Inc., H2 2012 102
Eisai Co., Ltd., H2 2012 103
Nippon Shinyaku Co., Ltd., H2 2012 104
Pfizer Inc., H2 2012 105
Teva Pharmaceutical Industries Limited, H2 2012 106
Cell Therapeutics, Inc., H2 2012 107
Exelixis, Inc., H2 2012 108
Aduro BioTech, H2 2012 109
Alfacell Corporation, H2 2012 110
Merck KGaA, H2 2012 111
GW Pharmaceuticals plc, H2 2012 112
Celldex Therapeutics, Inc., H2 2012 113
AEterna Zentaris Inc., H2 2012 114
ImmunoCellular Therapeutics, Ltd., H2 2012 115
Lixte Biotechnology Holdings, Inc., H2 2012 116
Northwest Biotherapeutics, Inc., H2 2012 117
Cleveland BioLabs, Inc., H2 2012 118
Oncolytics Biotech Inc., H2 2012 119
Oncothyreon Inc, H2 2012 120
Peregrine Pharmaceuticals, Inc., H2 2012 121
Telik, Inc., H2 2012 122
Pharmacyclics, Inc., H2 2012 123
PhytoMedical Technologies, Inc., H2 2012 124
Cytomedix, Inc., H2 2012 125
Transgene SA, H2 2012 126
Prana Biotechnology Limited, H2 2012 127
Threshold Pharmaceuticals, Inc., H2 2012 128
Natco Pharma Limited, H2 2012 129
Proximagen Neuroscience plc., H2 2012 130
e-Therapeutics plc, H2 2012 131
Rexahn Pharmaceuticals, Inc., H2 2012 132
Cancer Research Technology Limited, H2 2012 133
Spectrum Pharmaceuticals, Inc., H2 2012 134
Antisense Pharma GmbH, H2 2012 135
INSYS Therapeutics, Inc., H2 2012 136
Ambit Biosciences Corporation, H2 2012 137
Immupharma Plc, H2 2012 138
Adnexus Therapeutics, Inc., H2 2012 139
immatics biotechnologies GmbH, H2 2012 140
Advantagene, Inc., H2 2012 141
Apogenix GmbH, H2 2012 142
BioNumerik Pharmaceuticals, Inc., H2 2012 143
Ascenta Therapeutics, Inc., H2 2012 144
Oncoscience AG, H2 2012 145
Hawthorn Pharmaceuticals, Inc., H2 2012 146
Diffusion Pharmaceuticals LLC, H2 2012 147
MacroGenics, Inc., H2 2012 148
Fina Biotech, H2 2012 149
Arno Therapeutics, Inc., H2 2012 150
Merrimack Pharmaceuticals, Inc., H2 2012 151
Nobelpharma Co., Ltd., H2 2012 152
Deciphera Pharmaceuticals, LLC, H2 2012 153
Vascular Biogenics Ltd., H2 2012 154
Burzynski Research Institute, Inc., H2 2012 155
Stemline Therapeutics, Inc., H2 2012 156
BioCancell Therapeutics, Inc., H2 2012 157
Axelar AB, H2 2012 158
Advenchen Laboratories, LLC, H2 2012 159
Viral Genetics, Inc., H2 2012 160
NOXXON Pharma AG, H2 2012 161
ChemoCentryx, Inc., H2 2012 162
Cellceutix Corporation, H2 2012 163
TVAX Biomedical, LLC, H2 2012 164
Sirnaomics, Inc., H2 2012 165
to-BBB technologies BV, H2 2012 166
Lipopharma, H2 2012 167
ZGene A/S, H2 2012 168
Kringle Pharma, Inc., H2 2012 169
Nexgenix Pharmaceuticals, LLC, H2 2012 170
Archer Biosciences, Inc, H2 2012 171
Regulus Therapeutics Inc., H2 2012 172
Lee's Pharmaceutical Holdings Limited, H2 2012 173
Lipocine Inc., H2 2012 174
n.v. BRUCELLS s.a., H2 2012 175
R&D Systems, Inc., H2 2012 176
Eurofarma, H2 2012 177
TAU Therapeutics, LLC, H2 2012 178
EirGen Pharma Ltd., H2 2012 179
Tocagen Inc, H2 2012 180
Ampio Pharmaceuticals, Inc., H2 2012 181
CytomX, LLC., H2 2012 182
Assessment by Monotherapy Products, H2 2012 183
Assessment by Combination Products, H2 2012 184
Assessment by Stage and Route of Administration, H2 2012 186
Assessment by Stage and Molecule Type, H2 2012 188
Glioma Therapeutics Drug Profile Updates 269
Glioma Therapeutics Discontinued Products 279
Glioma Therapeutics Discontinued Products (Contd..1) 280
Glioma Therapeutics Discontinued Products (Contd..2) 281
Glioma Therapeutics Discontinued Products (Contd..3) 282
Glioma Therapeutics Discontinued Products (Contd..4) 283
Glioma Therapeutics Discontinued Products (Contd..5) 284
Glioma Therapeutics Dormant Products 285
Glioma Therapeutics Dormant Products (Contd..1) 286
Glioma Therapeutics Dormant Products (Contd..2) 287
Glioma Therapeutics Dormant Products (Contd..3) 288
Glioma Therapeutics Dormant Products (Contd..4) 289
Glioma Therapeutics Dormant Products (Contd..5) 290
Glioma Therapeutics Dormant Products (Contd..6) 291
Glioma Therapeutics Dormant Products (Contd..7) 292
Glioma Therapeutics Dormant Products (Contd..8) 293
Glioma Therapeutics Dormant Products (Contd..9) 294
Glioma Therapeutics Dormant Products (Contd..10) 295
Glioma Therapeutics Dormant Products (Contd..11) 296
Glioma Therapeutics Dormant Products (Contd..12) 297
Glioma Therapeutics Dormant Products (Contd..13) 298
Glioma Therapeutics Dormant Products (Contd..14) 299
Glioma Therapeutics Dormant Products (Contd..15) 300
Glioma Therapeutics Dormant Products (Contd..16) 301
Glioma Therapeutics Dormant Products (Contd..17) 302
Glioma Therapeutics Dormant Products (Contd..18) 303
Glioma Therapeutics Dormant Products (Contd..19) 304
Glioma Therapeutics Dormant Products (Contd..20) 305
Glioma Therapeutics Dormant Products (Contd..21) 306
Glioma Therapeutics Dormant Products (Contd..22) 307
Glioma Therapeutics Dormant Products (Contd..23) 308
Glioma Therapeutics Dormant Products (Contd..24) 309
Glioma Therapeutics Dormant Products (Contd..25) 310
Glioma Therapeutics Dormant Products (Contd..26) 311
Glioma Therapeutics Dormant Products (Contd..27) 312
Glioma Therapeutics Dormant Products (Contd..28) 313
Glioma Therapeutics Dormant Products (Contd..29) 314
Glioma Therapeutics Dormant Products (Contd..30) 315

List of Chart


Number of Products under Development for Glioma, H2 2012 18
Products under Development for Glioma Comparative Analysis, H2 2012 19
Products under Development by Companies, H2 2012 20
Products under Investigation by Universities/Institutes, H2 2012 29
Late Stage Products, H2 2012 39
Mid Clinical Stage Products, H2 2012 40
Early Clinical Stage Products, H2 2012 41
Discovery and Pre-Clinical Stage Products, H2 2012 42
Assessment by Monotherapy Products, H2 2012 183
Assessment by Combination Products, H2 2012 184
Assessment by Route of Administration, H2 2012 185
Assessment by Stage and Route of Administration, H2 2012 186
Assessment by Molecule Type, H2 2012 187
Assessment by Stage and Molecule Type, H2 2012 188

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *